Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTORISC pilote
2023-506329-12-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Apr 2024
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitrous oxide + oxygen in suicidal ideation, major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by CHRU Tours. Primary endpoint: Intensity/severity of suicidal ideation. Planned start Apr 2024; status: authorised.
02
Drugs
nitrous oxide + oxygen
03
Conditions
suicidal ideationmajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on 2023-506329-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506329-12-00.